RNAM vs. MCK

Last updated Jun 3, 2026

RNAM (Avidity Biosciences, Inc.) and MCK (McKesson Corporation) are both stocks. Both are in the Healthcare sector — RNAM in Biotechnology, MCK in Medical Distribution.

Performance

RNAM vs. MCK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Avidity Biosciences, Inc. (RNAM) and McKesson Corporation (MCK). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RNAM

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

MCK

• 1D: 0.37%
• 1M: -8.36%
• YTD: -9.67%
• 6M: -8.00%
• 1Y: 3.87%
• 3Y*: 24.32%
• 5Y*: 31.27%
• 10Y*: 15.65%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RNAM vs. MCK - Yearly Performance Comparison

	2026 (YTD)
RNAM Avidity Biosciences, Inc.	0.00%
MCK McKesson Corporation	-23.96%

Fundamentals

Market Cap RNAM : $10.87B MCK : $90.74B
EPS RNAM : -$4.93 MCK : $38.38
PS Ratio RNAM : 539.42 MCK : 0.23
PB Ratio RNAM : 6.44 MCK : 13.12
Total Revenue (TTM) RNAM : $18.76M MCK : $403.43B
Gross Profit (TTM) RNAM : $14.60M MCK : $14.55B
EBITDA (TTM) RNAM : -$741.79M MCK : $6.91B

Return for Risk

RNAM vs. MCK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MCK

MCK Risk / Return Rank: 43
MCK Sharpe Ratio Rank: 45
MCK Sortino Ratio Rank: 40
MCK Omega Ratio Rank: 39
MCK Calmar Ratio Rank: 44
MCK Martin Ratio Rank: 45

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RNAM vs. MCK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Avidity Biosciences, Inc. (RNAM) and McKesson Corporation (MCK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	RNAM	MCK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.13	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.30	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.55	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.44	—

Drawdowns

Drawdown Indicators

	RNAM	MCK	Difference
Max Drawdown Largest peak-to-trough decline	—	-82.84%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-27.17%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-27.17%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-27.17%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-44.23%	—
Current Drawdown Current decline from peak	—	-25.64%	—
Average Drawdown Average peak-to-trough decline	—	-28.65%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	9.74%	—

Volatility

Volatility by Period

	RNAM	MCK	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.60%	—
Volatility (6M) Calculated over the trailing 6-month period	—	22.90%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	28.91%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	24.16%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	28.80%	—

Dividends

RNAM vs. MCK - Dividend Comparison

RNAM has not paid dividends to shareholders, while MCK's dividend yield for the trailing twelve months is around 0.44%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MCK McKesson Corporation	0.44%	0.37%	0.47%	0.50%	0.54%	0.72%	0.95%	1.16%	1.32%	0.80%	0.80%	0.53%
RNAM Avidity Biosciences, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials